Alzheimer's disease (AD) remains a global health challenge. Previous studies have reported
linkages between AD and multiple behavioural risk exposures, however, the underlying …

Alzheimer's disease (AD) is a priority health problem with a high cost to society and a large
consumption of medical and social resources. The management of AD patients is complex …

Alzheimer's disease (AD) is the most common chronic progressive neurodegenerative
disease in the elderly. It has an increasing prevalence and a growing health burden. One of …

Alzheimer's disease remains a prevailing neurodegenerative condition which has an array
physical, emotional, and financial consequences to patients and society. In the past decade …

Formaldehyde (FA) has been found to induce major Alzheimer's disease (AD)-like features
including cognitive impairment, Aβ deposition, and Tau hyperphosphorylation, suggesting …

Alzheimer's disease (AD) is a neurodegenerative disorder affecting 44 million people
worldwide. Although many issues (pathogenesis, genetics, clinical features, and …

Aims This study aimed to examine the therapeutic effects and response mechanisms of 4-OI
in Alzheimer's disease (AD). Methods In this study, network pharmacology was employed to …

Introduction Accumulation of β-amyloid (Aβ) in neurons of patients with Alzheimer's disease
(AD) inhibits the activity of key enzymes in mitochondrial metabolic pathways, triggering …

Background Medial temporal lobe atrophy (MTA) is a diagnostic marker for mild cognitive
impairment (MCI) and Alzheimer's disease (AD), but the accuracy of quantitative MTA …

Alzheimer's disease (AD) is characterized by immune system dysregulation, impacting both
central and peripheral immune responses. The study aimed to investigate the mechanism …